Cogent Biosciences (COGT) – Hot New Coverage
-
Baird Starts Cogent (COGT) at Outperform, Says '$16/share of our $20 price target to bezuclastinib for non-advanced SM'
-
Jefferies Assumes Cogent (COGT) at Buy, $20 PT
-
-
Back to COGT Stock Lookup